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ABSTRACT
b-Catenin is a key mediator in the canonical Wnt
signaling pathway, which plays important roles in
multiple developmental processes. Inappropriate
activation of this pathway leads to developmental
defects and development of certain cancers. Upon
Wnt signaling, b-catenin binds TCF/LEF transcrip-
tion factors. The TCF/LEF-b-catenin complex then
recruits a variety of transcriptional coactivators to
the promoter/enhancer region of Wnt-responsive
genes and activates target gene transcription. In
this article, we demonstrate that GRIP1-associated
coactivator 63 (GAC63), a recently identified nuclear
receptor (NR) coactivator, interacts with b-catenin.
The N-terminus of GAC63 is the binding site
for b-catenin, whereas a C-terminal fragment of
b-catenin including armadillo repeats 10–12 binds
to GAC63. Over-expression of GAC63 enhanced
the transcriptional activity of b-catenin, and also
greatly enhanced TCF/LEF-regulated reporter
gene activity in a b-catenin-dependent manner.
Endogenous GAC63 was recruited to TCF/LEF-
responsive enhancer elements when b-catenin
levels were induced by LiCl. In addition, reduction
of endogenous GAC63 level by small interfering
RNA (siRNA) inhibited TCF/LEF-mediated gene
transcription. Our findings reveal a new function
of GAC63 in transcriptional activation of Wnt-
responsive genes.
INTRODUCTION
b-CateninisakeycomponentofthecanonicalWntsignaling
pathway, which regulates a variety of developmental
processes including cell growth and diﬀerentiation (1–3).
Inappropriate activation of the Wnt signaling pathway is
implicated in the development of certain cancers, such as
colon cancer (4–7). In the absence of Wnt ligands, cyto-
plasmic b-catenin levels are kept low through continuous
proteasome-mediateddegradation,whichiscontrolledbya
complex that contains adenomatous polyposis coli (APC),
axin and glycogen synthase kinase-3b (GSK-3). These
proteins promote the phosphorylation of serine and
threonineresiduesintheNH2-terminalregionofb-catenin,
and target it for degradation by the ubiquitin-dependent
proteasome degradation pathway (6,8). Upon Wnt signal-
ing,thedegradationpathwayisinhibited,andsubsequently
b-catenin accumulates in the cytoplasm and nucleus.
Nuclear b-catenin binds to transcription factors such as
those belonging to the T-cell-speciﬁc transcription factor/
lymphoid enhancer-binding factor (TCF/LEF) family,
and activates the transcription of target genes (6), such
as the genes encoding cyclin D1, c-myc, matrix metallo-
proteinase-7, neuronal cell adhesion molecule, interleukin-
8, FGF20 and DKK1 (9–15), many of which are involved
in various developmental and oncogenic processes.
In the absence of b-catenin binding, TCF/LEF tran-
scription factors repress Wnt target gene transcription
by recruiting transcription corepressors such as Groucho/
TLE, CtBP and HDAC (16,17). In response to Wnt
signaling, b-catenin accumulates, binds to TCF/LEF
transcription factors and converts the repressor complex
intoatranscriptionalactivatorcomplexbydisplacementof
the corepressors from TCF/LEF and recruitment of
additional transcription coactivators. These additional
coactivators include histone acetyltransferase p300/
CBP (18–21), the SWI/SNF ATPase subunit Brg-1 (22),
p 160 coactivator GRIP1 (23), histone methyltransferase
CARM1(24), CoCoA (25), Legless (26), MED12 (27),
Paraﬁbromin/Hyrax (28), TRRAP/TIP60, ISW1,
MLL/Set1 (29) and the LIM protein FHL2 (30). Each
transcription coactivator contributes to a signal transduc-
tion pathway which transmits the activating signal
from the DNA-bound transcriptional activator protein to
speciﬁcdownstreamtargetsinthetranscriptionmachinery.
For example, a member of the SWI/SNF complex, Brg-1,
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around the promoter by means of an ATPase activity (22).
Here, we report the identiﬁcation of GRIP1-associated
coactivator, GAC63, as a novel coactivator for b-catenin.
GAC63, also known as HUEL, has recently been
identiﬁed as a nuclear receptor (NR) coactivator (31).
GAC63 interacts with the bHLH-PAS domain of
p160 coactivators as well as the ligand-binding domain
of some NRs, such as estrogen receptor (ER) and
androgen receptor (AR). Over-expression of GAC63
enhanced transcriptional activation by NRs in a hor-
mone-dependent manner. Although GAC63 can interact
with NR directly, its coactivator function depends on the
presence of a p160 coactivator with an intact N-terminal
bHLH-PAS domain. Thus, it functions as a secondary
coactivator in NR-mediated gene transcription. A link
between GAC63 and b-catenin was ﬁrst suggested by the
ﬁndings that both GAC63 and b-catenin interact with
androgen receptor (AR) and enhance AR function in an
androgen-dependent manner (31–34). Furthermore, a
variety of NR coactivators, such as CBP/p300, Brg-1,
p160 coactivators, CARM1 and CoCoA, also function as
coactivators in TCF/LEF-dependent gene transcription
(18–25). Because of these connections, we decided to test
whether GAC63 also acts as a coactivator in TCF/LEF-
mediated gene transcription.
MATERIALS AND METHODS
Plasmids
The following plasmids were described previously: pSG5.
HA-b-catenin, pSG5.HA-LEF1, pGEX-4T1-b-catenin,
luciferase reporter plasmid pGL3OT, GK1-LUC (25);
pSG5.HA-GAC63, pSG5.HA-GAC63 (1–200), pSG5.
HA-GAC63 (200–370), pSG5.HA-GAC63 (370–567),
pGEX-5X1-GAC63 (31). cDNA fragments encoding
the indicated b-catenin amino acids were ampliﬁed by
PCR and inserted into XhoI and BglII sites of pSG5.HA
vector as follows: b-catenin (1–140), b-catenin (140–664),
b-catenin (520–781), b-catenin (665–781).
GST pull-down assay
35S-labeled full-length GAC63 and its fragments, and
b-catenin and its fragments were synthesized in vitro
by using TNT-Quick coupled transcription/translation
system (Promega) according to the manufacturer’s proto-
col. GST pull-down assays were performed as described
previously (31). The amount of GST used as a control was
always greater than or equal to the amount of GST fusion
protein used.
Coimmunoprecipitation and immunoblotting
COS-7 cells were transfected with 3mg pSG5.HA-b-
catenin plasmid. Cell lysates were cleared with protein
A/G beads (Santa Cruz Biotechnology) for 1h at 48C.
Two micrograms of rabbit anti-GAC63 antibody (31) or
normal rabbit IgG (Santa Cruz Biotechnology) was added
to the cell lysates and incubated overnight at 48Co n
a rotator. Thirty microliters of protein A/G beads was
added and incubated for another 3h. Beads were washed
three times with RIPA buﬀer and subjected to SDS-
PAGE. Blots were probed with anti-b-catenin antibody
(Santa Cruz Biotechnology).
Transient transfection assay. Transient transfection
assays were performed with CV-1 cells in 12-well plates
as described previously (25,31). The amount of DNA
transfected was held constant in all cases by using
the appropriate amount of the empty vector pSG5.HA.
Forty-eight hours after transfection, cells were harvested
for luciferase activity assays. The results shown are the
means and standard deviations of triplicate points and are
representative of at least three independent experiments.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed with RKO cells treated with
or without 50mM LiCl for 45min as described previously
(31), using 2mg of anti-b-catenin antibody (Santa Cruz
Biotechnology), 2mg of anti-GAC63 antibody 1bg (31) or
2mg of normal rabbit IgG (Santa Cruz Biotechnology).
Immunoprecipitated, puriﬁed, chromosomal DNA was
used for PCR ampliﬁcation, using the following primers:
cyclin D1: þ128 to þ486, 50-CGGGGCAGCAGAAGCG
AGA-30 (forward) and 50-GTGAGTAGCAAAGAAACG
TGG-30 (reverse);  3892 to  3649, 50-GGTCCTCCCCG
CAGTCTTC-30 (forward) and 50-CTCTCCCCCGCAGT
CAGG-30 (reverse); human FGF20 promoter, forward
50-CTTTCATGTGTGTCTGGGCAGGTC-30 and reverse
50-CTTAAACCGGTCTCCTCTCAAC-30; human DKK1
promoter, forward 50-GGCCACTTTGATCTCACGCG
TC-30 and reverse 50-CTGGGAACTTGGGTGCCCTTG
CC-30. Quantitative real-time PCR reactions (QPCRs)
were performed with 2ml (from a total of 50ml) of immu-
noprecipitated chromosomal DNA with a Stratagene
Mx3000P Instrument, using the same primers as for
standard PCR.
RNA interference
RNA interference experiments were performed as
described previously (31) using Lipofectamine 2000
(Invitrogen). Small interfering RNA (siRNA) oligonucleo-
tides for GAC63 and scrambled siRNA were synthesized
by the USC Norris Comprehensive Cancer Center
Microchemical Core Laboratory, and annealed to form
duplexes. The following siRNA sequences were used:
si-GAC63#1, 50-GCUCUUGCCAGAGAGAAAAdTdT-30
(sense) and 50-UUUUCUCUCUGGCAAGAGCdTdT-30
(antisense); si-GAC63#2, 50-GAACCUCUCCAAGUAA
GAGdTdT-30 (sense) and 50-CUCUUACUUGGAGA
GGUUCdTdT-30 (antisense); si-control with scrambled
sequence (negative control siRNA having no perfect
matches to known human genes), 50-UUCUCCGAACG
UGUCACAUdTdT-30 (sense) and 50-AUGUGACACG
UUCGGAGAAdTdT-30 (antisense). Three days
after siRNA transfection, total SW480 cell RNA
was extracted with Trizol reagent (Invitrogen),
and subjected to reverse transcription (RT) by using
iScript cDNA Synthesis Kit (Bio-Rad). Two microliters
of RT product was subjected to QPCR analysis.
Nucleic Acids Research, 2007, Vol. 35, No. 6 2085The primers used were as follows: human GAC63,
50-GGCACCTTATTAGGCATGGT-30 (forward),
50-GAATTGCCCTTACTGATGGG-30 (reverse); human
cyclin D1, 50-GCG CCC TCG GTG TCC TAC TTC
AAA-30 (forward), 50-TCG GGC CGG ATG GAG TTG
TCG-30 (reverse); human b-actin, 50-ACCCCATCG
AGCACGGCATCG-30 (forward), 50-GTCACCGGAGT
CCATCACGATG-30 (reverse).
RESULTS
Interaction of GAC63 withb-catenin
Both b-catenin and GAC63 bind to AR and enhance
transcriptional activation by AR (31–34). We therefore
tested whether GAC63 can interact with b-catenin in vitro
using GST pull-down assays. GAC63 synthesized in vitro
speciﬁcally and eﬃciently bound to GST-b-catenin, while
GST alone was unable to pull down GAC63 (Figure 1A).
These data suggest that GAC63 binds b-catenin directly
in vitro.
To test for binding in vivo, we performed
coimmunoprecipitation assay. COS-7 cells were transi-
ently transfected with b-catenin, and cell lysates were
immunoprecipitated by anti-GAC63 antibody followed
by immunoblotting analysis with anti-b-catenin antibody.
b-catenin was coimmunoprecipitated by antibody against
GAC63, but not by normal rabbit IgG (Figure 1B). Thus,
these results indicate that GAC63 interacts with b-catenin
in vivo.
We also tested whether GAC63 binds to LEF1 in GST
pull-down assays. b-catenin synthesized in vitro bound
strongly and speciﬁcally to GST-LEF1 (Figure 1C, upper
panel), but GAC63 synthesized in vitro did not (Figure 1C,
lower panel). These results suggest that GAC63 cannot
interact directly with LEF1 in vitro.
Mapping of interaction domains inGAC63 and b-catenin
GAC63 has a zinc-ﬁnger-like motif at the N-terminus, two
leucine-zipper-like motifs at the central region and an
LXXLL motif and an acidic region at the C-terminus (35)
(Figure 2A). To narrow down the b-catenin interaction
domain in GAC63, a series of GAC63 deletion mutants
were synthesized in vitro, and tested for their binding
to GST-b-catenin. Among them, a fragment of the
N-terminal region (amino acids 1–200) eﬃciently and
speciﬁcally bound GST-b-catenin, but fragments of the
central region (amino acids 200–370) and the C-terminus
(amino acids 370–567) bound weakly or not at all
(Figure 2B). Taken together, these results suggest that
b-catenin directly binds to the N-terminus of GAC63.
b-catenin is composed of three domains: a regulatory
N-terminal region followed by 12 armadillo (Arm) repeats
and a C-terminal transactivation domain (36) (Figure 2A).
In order to determine the domain of b-catenin that
interacts with GAC63, we performed GST pull-down
Figure 2. Determination of interaction domains of GAC63 and
b-catenin. (A) Functional domains of GAC63 and b-catenin.
Numbers beneath each diagram indicate amino acids. LXXLL,
leucine-rich motif; LZ, leucine zipper-like motif. Numbered segments
of b-catenin represent armadillo repeats. (B) The indicated GAC63
fragments were synthesized in vitro and tested in GST pull-down assays
for binding to GST or GST-b-catenin. (C) The in vitro synthesized
b-catenin fragments were tested in GST pull-down assays for binding to
GST or GST-GAC63.
Figure 1. GAC63 interacts with b-catenin in vitro and in vivo.
(A) In GST pull-down assays, GST-b-catenin fusion protein was
bound to beads and incubated with in vitro synthesized and
35S-labeled
GAC63. Bound proteins were eluted and analyzed by SDS-PAGE
and autoradiography. (B) COS-7 cells were transfected with 3mg pSG5.
HA-b-catenin plasmid. The cell extracts were immunoprecipitated with
anti-GAC63 antibody or normal rabbit IgG. The immunoprecipitated
proteins were detected by immunoblot with anti-b-catenin antibody.
(C) b-catenin and GAC63 were translated in vitro and tested for
binding to GST or GST-LEF1.
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GST-GAC63 speciﬁcally bound a b-catenin fragment
consisting of Arm repeats 10–12 and the C-terminal
activation domain. No interaction was seen with the
N-terminus, Arm repeats 1–12 or the C-terminus alone
(Figure 2C). These results suggest that a C-terminal
fragment of b-catenin consisting of Arm repeats 10–12
and the C-terminal activation domain binds GAC63.
GAC63 functions as a b-catenin dependent
coactivator inTCF/LEF-mediated transcription
GAC63 is a secondary coactivator in NR-mediated
gene transcription. Although it can bind NR directly as
well as the p160 NR coactivator GRIP1, its coactivator
function depends on the presence of GRIP1 (31).
On the other hand, b-catenin can bind directly to TCF/
LEF proteins and activate TCF/LEF-mediated gene
transcription (6). Since GAC63 interacts with b-catenin,
we tested whether GAC63 also functions as a coactivator
in the TCF/LEF-mediated pathway in transient trans-
fection assays using the luciferase reporter plasmid
pGL3OT, which contains TCF/LEF-responsive elements.
As expected, b-catenin enhanced the reporter gene
activity by 6-fold (Figure 3A, assay 4). Over-expression
of GAC63 alone had little eﬀect on reporter gene activity
(Figure 3A, assays 2 and 3). However, over-expression
of GAC63 and b-catenin together dramatically and
synergistically increased reporter gene expression up to
60-fold (Figure 3A, assays 5 and 6). The over-expression
of GAC63 had no eﬀect on the level of b-catenin expres-
sed (data not shown). In another control experiment,
the mutant reporter plasmid pGL3OF, containing mutant
TCF/LEF-responsive elements, was not activated
by either b-catenin alone or b-catenin plus GAC63
(data not shown). These results, along with the inability
of GAC63 to bind directly to LEF1, suggest that
GAC63 functions as a secondary coactivator in
TCF/LEF-mediated transcriptional activation, i.e. the
coactivator function of GAC63 depends on the presence
of b-catenin.
To further evaluate this hypothesis, we tested the eﬀect
of GAC63 on the transcriptional activity of LEF1
fused to the Gal4 DNA-binding domain (DBD), in the
absence or presence of b-catenin. Gal4DBD-LEF1 fusion
protein itself only had a weak autonomous transactivation
activity to activate transcription of a reporter gene con-
taining Gal4 response elements, and b-catenin strongly
enhanced this activity (Figure 3B, assays 5 and 6). In
the absence of b-catenin, GAC63 had little eﬀect on the
Gal4-responsive reporter gene expression (Figure 3B,
assay 7); however, in the presence of b-catenin, GAC63
acted synergistically with b-catenin to enhance the
reporter gene expression (Figure 3B, assay 8). These
data further support the idea that GAC63 enhances LEF1
activity through b-catenin.
Since GAC63 enhances LEF1 transcriptional activity
through b-catenin, we then tested whether GAC63 could
aﬀect the transcriptional activity of b-catenin. In tran-
siently transfected CV1 cells, Gal4DBD-b-catenin fusion
protein showed modest autonomous transactivation
Figure 3. GAC63 functions as a b-catenin dependent coactivator in
TCF/LEF-mediated transcription. (A) CV-1 cells were transfected
in 12-well plates with 200ng pGL3OT reporter plasmid; 10ng
pSG5.HA-LEF1; 100ng pSG5.HA-b-catenin; and 200ng (þ)o r
400ng (þþ) pSG5.HA-GAC63 as indicated. Results shown are
representative of three independent experiments. (B) CV-1 cells were
transfected with 200ng of GK1-LUC reporter plasmid, 200ng of
plasmid encoding Gal4 DBD or Gal4-LEF1, either 400ng of GAC63
expression plasmid, or 200ng of b-catenin, or both. The luciferase
activity results shown are representative of three independent experi-
ments. (C) CV-1 cells were transfected with 200ng of GK1-LUC
reporter plasmid, 200ng of plasmid encoding Gal4 DBD or Gal4-b-
catenin, and 400ng of GAC63 expression plasmid as indicated. The
luciferase activity results shown are representative of three independent
experiments.
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reporter gene (Figure 3C, assay 3). This activity was
further enhanced (up to 7-fold) by co-expression of
GAC63 (Figure 3C, assay 4). Thus, GAC63 enhances
the transcriptional activity of b-catenin.
Endogenous GAC63 isrecruited to TCF/LEF-responsive
enhancer elements uponLiCl treatment
To test whether endogenous GAC63 is speciﬁcally
recruited to endogenous TCF/LEF-responsive enhancer
elements in vivo, we employed chromatin immunoprecipi-
tation (ChIP) assays to examine the cyclin D1 promoter in
RKO colon cancer cells upon the addition of LiCl,
a GSK-3b inhibitor. To determine the optimal concentra-
tion of LiCl to inhibit the degradation of b-catenin, RKO
cells were treated with diﬀerent concentrations of LiCl for
45min. As shown in Figure 4A, b-catenin protein levels
increased upon the addition of LiCl in a dose-dependent
manner. Thus, we decided to treat RKO cells with 50mM
LiCl for 45min in ChIP assays. As expected, b-catenin
was recruited to cyclin D1 promoter region after a 45-min
LiCl treatment. Similarly, endogenous GAC63 was also
recruited to this promoter upon the addition of LiCl
(Figure 4B). Normal IgG served as a negative control, and
the input chromatin levels from LiCl-treated or untreated
cells were equivalent. The recruitment of b-catenin
and GAC63 was speciﬁc for the promoter region of
cyclin D1 gene, because PCRs with primers for a region
3.6kb upstream which lacked TCF/LEF-binding sites
failed to produce a signal from the same immunoprecipi-
tated chromatin fraction. QPCR analysis conﬁrmed the
recruitment of b-catenin and GAC63 to the promoter
region of cyclin D1 upon LiCl treatment (Figure 4C). The
same immunoprecipitated chromatin fraction was also
tested by PCR using primers to amplify the promoter
regions of two other Wnt target genes, FGF20 and DKK1
(15). Both b-catenin and GAC63 were recruited to these
promoter regions upon LiCl treatment (Figure 4D).
Endogenous GAC63 isimportant forefficient
transcriptional activation by LEF1
Over-expression of GAC63 enhances LEF1-responsive
reporter gene expression (Figure 3A). To test for a
physiological role of endogenous GAC63 in the process
of transcriptional activation by LEF1, we examined the
eﬀect of reduced endogenous GAC63 on LEF1-regulated
cyclin D1 gene expression in SW480 colon cancer cells.
These cells contain a mutation in the adenomatous
polyposis coli protein, which regulates b-catenin
degradation. Thus, these cells have elevated levels of
wild-type b-catenin, and therefore they have elevated
expression of cyclin D1 mRNA and protein (25). Two
diﬀerent siRNAs targeting the human GAC63 sequence
speciﬁcally reduced the level of endogenous GAC63
mRNA (Figure 5A, upper panel) and protein
(Figure 5B, upper panel), while the non-speciﬁc control
siRNA did not. The expression of the LEF1- and
b-catenin-regulated cyclin D1 gene was inhibited by
40–50% in the presence of siRNA against GAC63, but
was not aﬀected by an equivalent amount of control
siRNA with scrambled sequence (Figure 5A, lower panel).
The eﬀect on cyclin D1 gene expression was speciﬁc, since
the results shown are normalized to the level of b-actin
transcripts. Thus, although many diﬀerent coactivators
are involved in mediating transcriptional activation by
LEF1 and b-catenin, endogenous GAC63 is important for
eﬃcient induction of the LEF1- and b-catenin-regulated
cyclin D1 gene.
DISCUSSION
The Wnt signaling pathway plays important roles
in multiple developmental processes and cancer (1–7).
Upon Wnt signaling, b-catenin associates with TCF/LEF
Figure 4. Endogenous GAC63 is recruited to TCF/LEF-responsive
cyclin D1 promoter region upon LiCl treatment. (A) RKO cells were
treated with diﬀerent concentrations of LiCl for 45min. Cell extracts
were tested by immunoblotting using anti-b-catenin antibody. (B) RKO
cells were grown with or without 50mM LiCl for 45min and analyzed
by chromain immunoprecipitation assays, using the indicated anti-
bodies for immunoprecipitation. The immunoprecipitated DNA was
ampliﬁed by PCR using primers to amplify the promoter region of
cyclin D1 gene and a region 3.6kb upstream. Results shown are
representative of two independent experiments. (C) QPCR analysis of
immunoprecipitated RKO cell chromosomal DNA using primers for
the TCF/LEF binding region of cyclin D1 gene was performed with 2ml
samples. The results are shown as percentage of input, are the mean
and S.D. from triplicate reactions, and are representative of two
independent experiments. (D) PCR analysis of immunoprecipitated
RKO cell chromosomal DNA using primers for the promoter regions
of FGF20 and DKK1 genes. Results shown are representative of two
independent experiments.
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tional coactivators to the promoter/enhancer regions of
Wnt-responsive genes. Here we report that GAC63 is a
novel binding partner and coactivator of b-catenin.
GAC63 binds b-catenin in vitro and in vivo, but does not
bind directly to LEF1 (Figure 1). Over-expression of
GAC63 enhanced TCF/LEF-mediated transcription in a
b-catenin-dependent manner (Figure 3). Taken together,
Figure 5. Endogenous GAC63 is important for eﬃcient transcriptional activation by LEF1. (A) SW480 cells were transfected with siRNA duplex
against GAC63 or a non-speciﬁc control siRNA duplex. After 72h, cells were harvested for either immunoblots or total RNA preparation. mRNA
was analyzed by RT-QPCR to measure the levels of human GAC63, cyclin D1 and b-actin transcripts. Results shown for GAC63 and cyclin D1
transcripts were normalized by the levels of b-actin transcripts and are representative of three independent experiments. A paired, two-tailed t-test
performed on the values from the three experiments indicated that the siRNA against GAC63 caused signiﬁcant decreases in the expression levels of
cyclin D1 mRNA (P¼0.0004 for 1 and P¼0.0008 for #2). For the three experiments, the mean decrease and 95% conﬁdence intervals were 85 5%
(#1) and 85 7% (#2) for GAC63 mRNA, and 46 12% (#1) and 51 7% (#2) for cyclin D1 mRNA. (B) Cell extracts were also tested by
immunoblotting using anti-GAC63 and anti-actin antibodies.
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coactivator in TCF/LEF-mediated transcriptional acti-
vation, that is, its coactivator function depends on the
presence of b-catenin. Moreover, upon LiCl treatment,
endogenous GAC63 is recruited to the promoter
regions of endogenous Wnt target genes, such as cyclin
D1, FGF20 and DKK1 (Figure 4). In addition, reduction
of endogenous GAC63 by siRNA inhibited the
TCF/LEF- and b-catenin-mediated expression of the
cyclin D1 gene by 40–50% in a cell line with constitutively
high levels of b-catenin and cyclin D1 expression
(Figure 5). The lack of complete inhibition by siRNA
could be due to residual GAC63, or the compensatory
eﬀects by other transcription coactivators, such as
CBP/p300, Brg-1, GRIP1, CARM1 and CoCoA, which
also bind to b-catenin and serve as secondary coactivators
for TCF/LEF transcription factors. Furthermore, GAC63
could be recruited to other regulatory sites on the cyclin
D1 promoter in addition to the TCF/LEF-binding site;
therefore, it is possible that the reduced cyclin D1
expression observed when GAC63 levels are reduced by
siRNA could be due to reduced GAC63 interactions at the
TCF/LEF site and other regulatory sites. While we do not
know whether GAC63 is required for b-catenin-mediated
up-regulation of cyclin D1 expression in all regulatory
settings, our data as a whole make a compelling case that
GAC63 plays an important role in b-catenin- and TCF/
LEF-mediated transcription. We therefore conclude that
GAC63 is a physiological component of TCF/LEF- and
b-catenin-mediated transactivation, and is important
for optimal transcriptional activation mediated by
b-catenin and TCF/LEF in at least some cases.
In previous studies, GAC63 has been shown to function
as a secondary coactivator for NRs by cooperating
with p160 coactivators (31). The current study shows
that GAC63 functions as a secondary coactivator
for another class of transcription factor, TCF/LEF,
by cooperating with b-catenin. GAC63 also works as
a primary coactivator for the aryl hydrocarbon receptor
(AHR), i.e. it binds directly to AHR (37). Thus, GAC63
functions as a general transcriptional coactivator for
multiple signaling pathways. However, we cannot rule
out the possibility that GAC63 could also act as
corepressor in certain conditions. A number of proteins
have been shown to act as either coactivator or
corepressor in a promoter-speciﬁc manner. For example,
members of the p160 coactivators, such as GRIP1,
function as glucocorticoid receptor (GR) coactivators.
However, at the promoters of certain GR target genes that
are repressed by hormone-activated GR, such as the
human collagenase-3 gene and osteocalcin gene, GRIP1
acts as a GR corepressor (38).
GAC63 functions as a coactivator in multiple signaling
pathways; however, the mechanisms by which GAC63
contributes to transcriptional activation are yet to be
established. GAC63 has an N-terminal region containing
a zinc-ﬁnger-like motif, a central domain containing two
leucine-zipper-like motifs, and a C-terminal region with
a LXXLL motif and an acidic region (35). One region
of the GAC63 protein (amino acids 127–196) was shown
to have sequence similarity (34%) to the DNA-binding
domain (amino acids 21–95) of the XPA DNA repair
protein (SWISS-PROT accession no. Q64029) (39).
Another GAC63 region (amino acids 239–533) shares
homology with members of the zinc transporter family.
In fragment studies, the N-terminus and central region of
GAC63 both bind GRIP1, while only the N-terminus
binds b-catenin. When fused to Gal4 DNA-binding
domain, the C-terminus of GAC63 showed weak auto-
nomous transcriptional activation activity (31). GAC63
also contains several nuclear localization signals and
a nuclear-export-like signal; the human ortholog of
GAC63, HUEL, has been shown to undergo nuclear
translocation during S phase (39).
b-Catenin has been shown to be a coactivator for TCF/
LEF transcription factors as well as androgen receptor.
This provides a mechanism for crosstalk between the Wnt
and AR signaling pathways. In addition, these two
pathways share a number of transcriptional coactivators,
such as CBP/p300 (18–21), Brg-1 (22), p160 coactivators
(23), CARM1 (24) and CoCoA (25). GAC63 provides
yet another example of a transcriptional coactivator that
is involved in both signaling pathways. Furthermore,
members of the NR superfamily, such as androgen recep-
tor (AR), thyroid hormone receptor (TR) and retinoic
acid receptor (RAR), have been shown to interfere with
the Wnt signaling pathway (32,40–45). The antagonistic
eﬀect by AR could be due to the competition for common
transcriptional coactivators, in addition to other proposed
mechanisms, such as increased degradation of b-catenin
(40,46).
In our study, GAC63 bound to a b-catenin fragment
consisting of Arm repeats 10–12 and the C-terminal acti-
vation domain. Several other proteins have been reported
to bind to a similar b-catenin subdomain, and contribute
to transcriptional activation. These proteins include
CBP/p300, MED12, Paraﬁbromin/Hyrax, TRRAP/
TIP60, ISW1 and MLL/Set1 (18,21,27–29,47). It remains
to be determined whether these coactivators can bind to
b-catenin at the same time and function synergistically as
coactivators, or whether some of them may compete for
binding and inhibit each other’s function or play diﬀerent
roles on various promoters. For example, although CBP
and p300 are closely related, they play opposite roles on
the expression of some b-catenin target genes, such as
survivin (48). The small molecule ICG-001, which blocks
the CBP–b-catenin interaction but not the p300–b-catenin
interaction, inhibits survivin gene expression. In the
absence of ICG-001, CBP is recruited to the survivin
promoter, and promotes survivin gene expression;
however, in the presence of ICG-001, there is less CBP
on the survivin promoter but more p300 instead, which
leads to concomitant recruitment of repressive elements
and results in transcription repression.
Inappropriate activation of the Wnt signaling pathway
occurs in many types of cancer, and is caused by muta-
tions of many of the Wnt signaling components (4–7).
The two genes found most frequently mutated are
adenomatous polyposis coli (APC) and b-catenin. These
mutations generally lead to stabilization of b-catenin, and
an over-activation of the Wnt signaling pathway. This
over-activation is thought in part to promote oncogenesis
2090 Nucleic Acids Research, 2007, Vol. 35, No. 6through over-expression of Wnt-responsive genes, such
as c-myc and cyclin D1 (9–11). Since GAC63 cooperates
with b-catenin to activate Wnt-responsive gene expression,
GAC63 might play a role in the oncogenic processes.
Furthermore, in DNA microarray studies, GAC63
(C4orf1) over-expression has been shown to be associated
with lymph node metastasis of breast cancer (49). In
addition, a distinct alternative transcript encoding GAC63
with a modiﬁed and truncated C-terminus was detected in
the HT-1080 ﬁbrosarcoma, G-401 Wilms tumor and SiHa
cervical carcinoma cell lines (35). These ﬁndings indicate
that GAC63 might be involved in the development
of cancer. The role of GAC63 in oncogenesis, and the
mechanisms by which GAC63 contributes to oncogenesis
are currently under investigation in our laboratory.
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